ATE173402T1 - Lyophilisierte stammzellenfaktor formulierungen - Google Patents

Lyophilisierte stammzellenfaktor formulierungen

Info

Publication number
ATE173402T1
ATE173402T1 AT95906058T AT95906058T ATE173402T1 AT E173402 T1 ATE173402 T1 AT E173402T1 AT 95906058 T AT95906058 T AT 95906058T AT 95906058 T AT95906058 T AT 95906058T AT E173402 T1 ATE173402 T1 AT E173402T1
Authority
AT
Austria
Prior art keywords
stem cell
cell factor
lyophilized
factor formulations
lyophilized stem
Prior art date
Application number
AT95906058T
Other languages
English (en)
Inventor
Susan I Hershenson
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE173402T1 publication Critical patent/ATE173402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95906058T 1993-12-22 1994-12-21 Lyophilisierte stammzellenfaktor formulierungen ATE173402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/172,507 US6288030B1 (en) 1993-12-22 1993-12-22 Stem cell factor formulations and methods

Publications (1)

Publication Number Publication Date
ATE173402T1 true ATE173402T1 (de) 1998-12-15

Family

ID=22627993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95906058T ATE173402T1 (de) 1993-12-22 1994-12-21 Lyophilisierte stammzellenfaktor formulierungen

Country Status (14)

Country Link
US (4) US6288030B1 (de)
EP (1) EP0732935B1 (de)
CN (1) CN1105575C (de)
AT (1) ATE173402T1 (de)
AU (1) AU696860B2 (de)
CA (1) CA2182970C (de)
DE (1) DE69414723T2 (de)
DK (1) DK0732935T3 (de)
ES (1) ES2123951T3 (de)
HK (1) HK1008815A1 (de)
IL (1) IL112088A (de)
NZ (1) NZ278252A (de)
WO (1) WO1995017206A1 (de)
ZA (1) ZA9410189B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9515839D0 (en) * 1995-08-02 1995-10-04 Q One Biotech Ltd Feline stem cell factor
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6472208B1 (en) * 1999-12-13 2002-10-29 Héma-Québec Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells
AU2020902A (en) * 2000-12-06 2002-06-18 Robert J Hariri Method of collecting placental stem cells background of the invention
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2336300B1 (de) 2001-02-14 2015-07-08 Anthrogenesis Corporation Post-partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3963786B2 (ja) * 2002-06-11 2007-08-22 富士通株式会社 情報処理装置
AU2003298775B2 (en) * 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
CA2515594A1 (en) * 2003-02-13 2004-08-26 Anthrogenesis Corporation Use of umbilical cord blood to treat individuals having a disease, disorder or condition
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
AU2004296765B2 (en) * 2003-12-02 2011-03-24 Celgene Corporation Methods and compositions for the treatment and management of hemoglobinopathy and anemia
WO2005067889A1 (en) 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
CA2615731A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
PE20070771A1 (es) 2005-10-13 2007-08-11 Anthrogenesis Corp Inmunomodulacion mediante el uso de celulas madres de la placenta
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
ES2671355T3 (es) 2005-12-29 2018-06-06 Anthrogenesis Corporation Poblaciones de células madre placentarias
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
EP2084268B1 (de) * 2006-10-23 2018-09-26 Celularity, Inc. Verfahren und zusammensetzungen zur behandlung von knochendefekten mit plazenta-zellpopulationen
CA2677397C (en) 2007-02-12 2016-04-05 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
KR101645311B1 (ko) * 2007-09-26 2016-08-03 안트로제네시스 코포레이션 인간 태반 관류액으로부터의 혈관형성 세포
KR20190132556A (ko) 2007-09-28 2019-11-27 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
CN101909694A (zh) * 2007-11-07 2010-12-08 人类起源公司 脐带血在治疗早产并发症中的用途
PE20110400A1 (es) * 2008-08-20 2011-06-22 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas
WO2010021715A1 (en) * 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
CA2965883C (en) * 2008-08-22 2020-05-12 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
KR20110086176A (ko) * 2008-11-19 2011-07-27 안트로제네시스 코포레이션 양막 유래 부착성 세포
BRPI0921999B8 (pt) * 2008-11-21 2021-05-25 Anthrogenesis Corp uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
MX353489B (es) 2009-07-02 2018-01-16 Anthrogenesis Corp Metodo para producir eritrocitos sin celulas alimentadoras.
WO2011094181A1 (en) * 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
JP6097684B2 (ja) 2010-04-07 2017-03-15 アントフロゲネシス コーポレーション 胎盤幹細胞を用いる血管形成
JP2013523823A (ja) 2010-04-08 2013-06-17 アントフロゲネシス コーポレーション 胎盤幹細胞を用いるサルコイドーシスの治療
CN103097520B (zh) 2010-07-13 2017-12-05 人类起源公司 产生自然杀伤细胞的方法
EP3241558B1 (de) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Hochlösliche leptine
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
EP2714059B1 (de) 2011-06-01 2018-10-03 Celularity, Inc. Schmerzbehandlung mithilfe von stammzellen aus der plazenta
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
EP3622960A1 (de) 2013-02-05 2020-03-18 Celularity, Inc. Natürliche killerzellen aus plazenta
PL3334747T3 (pl) 2015-08-13 2024-04-02 Amgen Inc. Naładowana filtracja wgłębna białek wiążących antygen

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
JPS5534001A (en) * 1978-08-28 1980-03-10 Noda Sangyo Kagaku Kenkyusho Stabilization of sarcosine oxidase
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
EP0035204B2 (de) 1980-03-05 1991-05-22 Miles Inc. Pasteurisierte therapeutisch aktive Proteinzusammensetzungen
JPS5874617A (ja) 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
JPS58134991A (ja) * 1981-12-28 1983-08-11 Takeda Chem Ind Ltd セラチオペプチタ−ゼの安定化法
JPS59134730A (ja) 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
NZ226170A (en) 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
DE69010518T2 (de) 1989-01-30 1994-11-03 Corint Ltd Wässerige Desmopressin-CMC enthaltende Arzneizubereitung.
JPH02268681A (ja) * 1989-04-07 1990-11-02 Green Cross Corp:The ウロキナーゼ前駆体の安定化方法及び乾燥製剤
WO1990012029A1 (en) * 1989-04-11 1990-10-18 Immunobiology Research Institute, Inc. Lyophilized peptide formulations
WO1991005795A1 (en) 1989-10-16 1991-05-02 Amgen Inc. Stem cell factor
DE69033584T2 (de) 1989-10-16 2001-03-08 Amgen Inc Stammzellenfaktor
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
AU8196891A (en) 1990-06-25 1992-01-23 Immunex Corporation Mast cell growth factor
SK279641B6 (sk) * 1991-12-20 1999-01-11 Novo Nordisk A/S Stabilizovaný farmaceutický prípravok obsahujúci r
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
DE69329795T2 (de) * 1992-10-02 2001-07-05 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator

Also Published As

Publication number Publication date
AU1442295A (en) 1995-07-10
CN1142771A (zh) 1997-02-12
EP0732935A1 (de) 1996-09-25
CA2182970C (en) 2000-11-28
DE69414723T2 (de) 1999-07-22
US5965522A (en) 1999-10-12
DK0732935T3 (da) 1999-08-02
ES2123951T3 (es) 1999-01-16
NZ278252A (en) 1998-04-27
EP0732935B1 (de) 1998-11-18
IL112088A (en) 2001-04-30
WO1995017206A1 (en) 1995-06-29
ZA9410189B (en) 1995-08-25
US6288030B1 (en) 2001-09-11
AU696860B2 (en) 1998-09-17
US20020013258A1 (en) 2002-01-31
CA2182970A1 (en) 1995-06-29
US6020469A (en) 2000-02-01
CN1105575C (zh) 2003-04-16
DE69414723D1 (de) 1998-12-24
HK1008815A1 (en) 1999-05-21
IL112088A0 (en) 1995-03-15

Similar Documents

Publication Publication Date Title
DE69414723D1 (de) Lyophilisierte stammzellenfaktor formulierungen
FI952119A (fi) Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus
DK0758248T3 (da) Formuleringer til faktor IX
GR3006172T3 (de)
DK289285D0 (da) Thymopentin analoge
AU5327386A (en) Peptide derivatives, analogous to pepstatin, which inhibit renin and acid proteases.
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
FI955130A (fi) L-aminohappo-oksidaasi
NO163619C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro- 2-heterocykloalkylpyrido(4,3)indoler.
ES2181763T3 (es) Formulaciones a base de fenbendazol.
ES2058479T3 (es) Compuestos peptidicos.
ATE41773T1 (de) 4,5-dihydro-4-oxo-2((2-transphenylcyclopropyl)amino>-3-furancarbonsaeuren und derivate davon.
FI945252A0 (fi) Stabiileja lyofilisoituja tiotepakoostumuksia
DE69521315T2 (de) Hirudin enthaltende pharmazeutische zusammensetzungen
DE3152363T1 (de)
AU639751B2 (en) Temporary minimal protection synthesis of lh-rh analogs
IT8423664A0 (it) Realizzate in applicazione al detto metodo per la produzione metodo. industriale di calzature, in particolare ciabatte, di notevole leggerezza ed utilizzabili sia da casa che all'aperto, e calzature
NO853069L (no) 2,5-pyrolidindion-derivater.
IT8420913A0 (it) Leggerezza ed utilizzabili sia da metodo per la produzione casa che all'aperto, e calzature industriale di calzature, in realizzate in applicazione al detto particolare ciabatte, di notevole metodo.
ATE74764T1 (de) Peptidische zusammensetzung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee